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Purpose: The advent of modern neuroimaging with computed 
tomography (CT) and magnetic resonance (MR) imaging has 
allowed for a better diagnosis and characterization of brain 
abnormalities and diseases. Despite the deep insights offered 
by these imaging methods, their sensitivity and/or spatial 
resolution are insufficient to study the structures of this very 
complex tissue at the cellular level. X-ray phase contrast 
imaging may provide the opportunity to overcome many of 
the limitations affecting current diagnostic methods [1-8].  
Materials/methods: Pre-clinical imaging on the micro- and 
nano-scale with multidimensional resolution (spatial, 
temporal and chemical) is possible when high intensity, 
energy selective and collimated photon beam are used. 
Advanced X-ray phase contrast imaging techniques have been 
developed and used for investigating excised rat and human 
cerebella without the application of any stain or contrast 
agent.  
Results: Images clearly depict the hippocampus and 
cerebellum regions (with white and gray matter) and the 
substantia nigra structure. Normal and tumor tissues are also 
effectively discriminated.  
Conclusions: Proof of principle studies in phase contrast 
micro-CT were performed on irradiated rat brains, 
demonstrating the ability of the method in visualizing not 
only the fine architecture of the organ but also the effects of 
the treatment. Data are validated by comparison with 
histology. This presentation will give an overview of the 
recent results produced in pre-clinical neuroimaging 
research. 
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Purpose: Alanine pellets provided by the National Physical 
Laboratory (UK) have been proposed as a dose verification 
tool in hadron beams. Multiple studies demonstrate a 
relatively weak and reproducible dependence on the mixed 
radiation environment found in Spread out Bragg peaks in ion 
therapy. Quenching effects can be modeled with little effort, 
in conjunction with Monte Carlo particle transport codes [1]. 
Methods: During the in-vivo irradiation with C-12 ions 
presented in the paper [2] several pellets of Alanine were 
positioned at the same SOBP depth where the tumor target 
was located. Alanine pellets were provided and read out by 
NPL in Teddington, UK. The resulting dose-to-water is 
translated to dose-to-alanine, and compared with the 
quenching corrected calculated dose-to-alanine calculated 
with Monte Carlo simulations. 
The Monte Carlo particle transport code FLUKA was used to 
simulate the mixed particle spectrum along the beam. The 
Hansen & Olsen response model [1,3] is provided as a user 
function and linked into the FLUKA runtime.  
Results: Most experimental dose-to-alanine valued agree 
within a few percent to the predicted and quenching 
corrected values. Quenching factors are found to be around 
0.75 at the center of a 3 g/cm2 wide Carbon ion SOBP, 7.3 
g/cm2 deep with a dose average LET of ~60 keV/µm. 
Conclusions: We have successfully demonstrated the use of 
the Alanine dosimeter in an in-vivo dose verification setting. 
Alanine pellets appear to be a robust solid state dosimeter, 
provided information of the mixed radiation field can be 
retrieved by supplemental Monte Carlo calculations. 
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Purpose: Experimental evidence suggests a variable relative 
biological effectiveness (RBE) of clinical proton beams. As 
the spread in data is large a conservative choice of 1.1 is 
used in clinical practice world-wide. Due to an increasing 
interest several radio-biological models have been developed 
trying to represent the complex dependencies that determine 
RBE. We compare predictions obtained from such models for 
clinical-like cranial irradiations. 
Material/methods: Three models proposed in the literature 
[1,2,3] were implemented to an in-house Monte-Carlo-based 
dose forward-calculation engine [4,5]. They were applied to 
